Fintel reports that on November 8, 2024, Goldman Sachs upgraded their outlook for BioNTech SE - Depositary Receipt () ...

with key indications including first-line non-small cell lung cancer is potentially sizable, first-line triple-negative ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yaron Werber ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...

In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ ... as did their stock prices. But three years later, times have changed dramatically for both companies.

BioNTech stock target cut to $122 from $132 by TD Cowen On Tuesday, TD Cowen maintained a Hold rating on BioNTech (NASDAQ:BNTX) shares but lowered the price target to $122 from the previous $132. The ...